Patent · US Active

Substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amines and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of embryonic ectoderm development (EED) protein

US11981678B2 · kind B2 · utility

0Cited by
0References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 29, 2022
Grant dateMay 14, 2024
Priority date
Expiry dateApr 29, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/04
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

Disclosed are compounds that bind to embryonic ectoderm development (EED) protein and proteolysis-targeting chimeric (PROTAC) derivatives thereof that induce degradation of EED. The disclosed compounds may be characterized as substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amine compounds. The disclosed PROTAC derivatives thereof typically include a first targeting moiety that binds to EED (MEED) which may be derived from the disclosed [1,2,4]triazolo[4,3-c]pyrimidin-5-amine compounds that bind to EED. The first targeting moiety typically is linked via a bond or a linker (L) to a second targeting moiety that binds to an E3 ubiquitin ligase (ME3). As such, the disclosed PROTACS may be described as having a formula MEED-L-ME3 or ME3-L-MEED, wherein MEED has a formula of where R2, n, and x are as described herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.